N-Desmethyl ponatinib

Ponatinib Active Metabolite AP24567 (M42) is a research reagent applied in pharmaceuticals and cancer treatment. Ponatinib Active Metabolite AP24567 (M42) is an analog of Ponatinib (P688250) which is a tyrosine kinase inhibitors (TKI) and used to treat chronic myeloid leukemia (CML) (1,2,3) . Ponatinib (P688250) is also used in combination with other drugs, such as forskolin, to combat TKI resistance in patient with CML (3), targeted drug in small-cell lung cancer. Potent FAK inhibitor. FGFR/VEGFR/Bcr-Abl inhibitor It is a COVID19-related research product.

N-Desmethyl ponatinib is supplied with detailed characterization data compliant with regulatory guideline. N-Desmethyl ponatinib can be used for analytical method development, method validation (AMV), Quality Control (QC) application for Abbreviated New Drug Application (ANDA), or during commercial production of Ponatinib.

Ponatinib Active Metabolite AP24567 (M42) is a research reagent applied in pharmaceuticals and cancer treatment. Ponatinib Active Metabolite AP24567 (M42) is an analog of Ponatinib (P688250) which is a tyrosine kinase inhibitors (TKI) and used to treat chronic myeloid leukemia (CML) (1,2,3) . Ponatinib (P688250) is also used in combination with other drugs, such as forskolin, to combat TKI resistance in patient with CML (3), targeted drug in small-cell lung cancer. Potent FAK inhibitor. FGFR/VEGFR/Bcr-Abl inhibitor It is a COVID19-related research product.